Target Information
Target General Infomation | |||||
---|---|---|---|---|---|
Target ID |
T29130
|
||||
Former ID |
TTDS00275
|
||||
Target Name |
Signal transducer and activator of transcription 3
|
||||
Gene Name |
STAT3
|
||||
Synonyms |
Stat3; Transcription factor STAT3; STAT3
|
||||
Target Type |
Successful
|
||||
Disease | Hepatocellular carcinoma [ICD9: 155; ICD10: C22.0] | ||||
Multiple myeloma [ICD9: 203; ICD10: C90] | |||||
Psoriasis [ICD9: 696; ICD10: L40] | |||||
Solid tumours [ICD9: 140-199, 210-229; ICD10: C00-D48] | |||||
Function |
Signal transducer and transcription activator that mediates cellular responses to interleukins, KITLG/SCF and other growth factors. May mediate cellular responses to activated FGFR1, FGFR2, FGFR3 and FGFR4. Binds to the interleukin-6 (IL-6)- responsive elements identified in the promoters of various acute- phase protein genes. Activated by IL31 through IL31RA. Cytoplasmic STAT3 represses macroautophagy by inhibiting EIF2AK2/PKR activity. Plays an important role in host defense in methicillin-resistant S.aureus lung infection by regulating the expression of the antimicrobial lectin REG3G (By similarity).
|
||||
BioChemical Class |
Transcription factor
|
||||
Target Validation |
T29130
|
||||
UniProt ID | |||||
Sequence |
MAQWNQLQQLDTRYLEQLHQLYSDSFPMELRQFLAPWIESQDWAYAASKESHATLVFHNL
LGEIDQQYSRFLQESNVLYQHNLRRIKQFLQSRYLEKPMEIARIVARCLWEESRLLQTAA TAAQQGGQANHPTAAVVTEKQQMLEQHLQDVRKRVQDLEQKMKVVENLQDDFDFNYKTLK SQGDMQDLNGNNQSVTRQKMQQLEQMLTALDQMRRSIVSELAGLLSAMEYVQKTLTDEEL ADWKRRQQIACIGGPPNICLDRLENWITSLAESQLQTRQQIKKLEELQQKVSYKGDPIVQ HRPMLEERIVELFRNLMKSAFVVERQPCMPMHPDRPLVIKTGVQFTTKVRLLVKFPELNY QLKIKVCIDKDSGDVAALRGSRKFNILGTNTKVMNMEESNNGSLSAEFKHLTLREQRCGN GGRANCDASLIVTEELHLITFETEVYHQGLKIDLETHSLPVVVISNICQMPNAWASILWY NMLTNNPKNVNFFTKPPIGTWDQVAEVLSWQFSSTTKRGLSIEQLTTLAEKLLGPGVNYS GCQITWAKFCKENMAGKGFSFWVWLDNIIDLVKKYILALWNEGYIMGFISKERERAILST KPPGTFLLRFSESSKEGGVTFTWVEKDISGKTQIQSVEPYTKQQLNNMSFAEIIMGYKIM DATNILVSPLVYLYPDIPKEEAFGKYCRPESQEHPEADPGSAAPYLKTKFICVTPTTCSN TIDLPMSPRTLDSLMQFGNNGEGAEPSAGGQFESLTFDMELTSECATSPM |
||||
Drugs and Mode of Action | |||||
Target Expression Profile (TEP) and Drug Resistance Mutation (DRM) | |||||
TEP | EXP Info | ||||
Pathways | |||||
KEGG Pathway | Chemokine signaling pathway | ||||
HIF-1 signaling pathway | |||||
FoxO signaling pathway | |||||
Signaling pathways regulating pluripotency of stem cells | |||||
Jak-STAT signaling pathway | |||||
Prolactin signaling pathway | |||||
Adipocytokine signaling pathway | |||||
Toxoplasmosis | |||||
Hepatitis C | |||||
Hepatitis B | |||||
Measles | |||||
Epstein-Barr virus infection | |||||
Pathways in cancer | |||||
Viral carcinogenesis | |||||
Proteoglycans in cancer | |||||
MicroRNAs in cancer | |||||
Pancreatic cancer | |||||
Acute myeloid leukemia | |||||
Inflammatory bowel disease (IBD) | |||||
PANTHER Pathway | Angiogenesis | ||||
EGF receptor signaling pathway | |||||
Inflammation mediated by chemokine and cytokine signaling pathway | |||||
Interleukin signaling pathway | |||||
JAK/STAT signaling pathway | |||||
PDGF signaling pathway | |||||
Ras Pathway | |||||
CCKR signaling map ST | |||||
Pathway Interaction Database | GMCSF-mediated signaling events | ||||
IL27-mediated signaling events | |||||
Signaling events mediated by PTP1B | |||||
IL12-mediated signaling events | |||||
Signaling events mediated by TCPTP | |||||
Signaling events mediated by HDAC Class I | |||||
IL2-mediated signaling events | |||||
CXCR4-mediated signaling events | |||||
EGF receptor (ErbB1) signaling pathway | |||||
IFN-gamma pathway | |||||
ErbB1 downstream signaling | |||||
ErbB2/ErbB3 signaling events | |||||
IL6-mediated signaling events | |||||
PDGFR-beta signaling pathway | |||||
Neurotrophic factor-mediated Trk receptor signaling | |||||
IL23-mediated signaling events | |||||
Signaling events mediated by Stem cell factor receptor (c-Kit) | |||||
FGF signaling pathway | |||||
RAC1 signaling pathway | |||||
Notch-mediated HES/HEY network | |||||
IL12 signaling mediated by STAT4 | |||||
Reactome | Interleukin-6 signaling | ||||
Senescence-Associated Secretory Phenotype (SASP) | |||||
POU5F1 (OCT4), SOX2, NANOG activate genes related to proliferation | |||||
Transcriptional regulation of pluripotent stem cells | |||||
Growth hormone receptor signaling | |||||
WikiPathways | Serotonin Receptor 2 and STAT3 Signaling | ||||
Notch Signaling Pathway | |||||
Interferon type I signaling pathways | |||||
EPO Receptor Signaling | |||||
TGF Beta Signaling Pathway | |||||
IL-2 Signaling Pathway | |||||
EGF/EGFR Signaling Pathway | |||||
IL-4 Signaling Pathway | |||||
IL-6 signaling pathway | |||||
Signaling of Hepatocyte Growth Factor Receptor | |||||
Kit receptor signaling pathway | |||||
Nuclear Receptors Meta-Pathway | |||||
Estrogen Receptor Pathway | |||||
TCA Cycle Nutrient Utilization and Invasiveness of Ovarian Cancer | |||||
IL-3 Signaling Pathway | |||||
Dopaminergic Neurogenesis | |||||
Transcriptional regulation of pluripotent stem cells | |||||
Mammary gland development pathway - Involution (Stage 4 of 4) | |||||
Signaling by SCF-KIT | |||||
Interleukin-6 signaling | |||||
Growth hormone receptor signaling | |||||
JAK/STAT | |||||
PDGF Pathway | |||||
BDNF signaling pathway | |||||
Oncostatin M Signaling Pathway | |||||
Adipogenesis | |||||
Interleukin-11 Signaling Pathway | |||||
AGE/RAGE pathway | |||||
Prostate Cancer | |||||
TSLP Signaling Pathway | |||||
IL-9 Signaling Pathway | |||||
IL17 signaling pathway | |||||
IL-7 Signaling Pathway | |||||
Regulation of Microtubule Cytoskeleton | |||||
Leptin signaling pathway | |||||
TSH signaling pathway | |||||
Cell Differentiation - Index | |||||
Cell Differentiation - meta | |||||
Signaling by PDGF | |||||
NGF signalling via TRKA from the plasma membrane | |||||
TFs Regulate miRNAs related to cardiac hypertrophy | |||||
MicroRNAs in cardiomyocyte hypertrophy | |||||
Physiological and Pathological Hypertrophy of the Heart | |||||
Androgen receptor signaling pathway | |||||
IL-5 Signaling Pathway | |||||
References | |||||
Ref 523569 | ClinicalTrials.gov (NCT01406574) Phase I/II Study of OPB-31121 in Patients With Progressive Hepatocellular Carcinoma. U.S. National Institutes of Health. | ||||
Ref 524640 | ClinicalTrials.gov (NCT02058017) OPB-51602 in Locally Advanced Nasopharyngeal Carcinoma Prior to Definitive Chemoradiotherapy. U.S. National Institutes of Health. | ||||
Ref 531262 | Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6. Epub 2010 Oct 21.In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). | ||||
Ref 532231 | OPB-31121, a novel small molecular inhibitor, disrupts the JAK2/STAT3 pathway and exhibits an antitumor activity in gastric cancer cells. Cancer Lett. 2013 Jul 10;335(1):145-52. | ||||
Ref 533115 | Phase I and biomarker study of OPB-51602, a novel signal transducer and activator of transcription (STAT) 3 inhibitor, in patients with refractory solid malignancies. Ann Oncol. 2015 May;26(5):998-1005. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.